Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02431702 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
A Phase 3 study, sponsored by Janssen Scientific Affairs.
- Completed
- Registry status
- Phase 3
- Development phase
- 337
- Enrollment target
NCT02431702 is a Phase 3 study that has completed, run by Janssen Scientific Affairs. The registered enrollment target is 337 participants.
The verdict
NCT02431702, a Phase 3 study, has completed, sponsored by Janssen Scientific Affairs.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 337 participants
- Enrollment target
Study Summary
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP \[that is oral paliperidone extended release {ER}, oral risperidone, or another OAP\]) in delaying time to treatment failure. The study will also evaluate changes in cognition, functioning, brain intracortical myelin (ICM) volume following treatment with PP compared with OAP in participants with recent-onset schizophrenia or schizophreniform disorder.
Interventions
- DRUG Haloperidol
- DRUG Olanzapine
- DRUG Aripiprazole
- DRUG Perphenazine
- DRUG Oral Paliperidone ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2015-07-08 |
| Est. Completion | 2019-11-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02431702
The ClinicalTrials.gov registry entry for NCT02431702 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 337 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Scientific Affairs, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Haloperidol is the first listed.
NCT02431702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02431702 about?
NCT02431702 is a clinical study titled "A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform". The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP \[that is oral paliperidone extended release {ER}, oral risperidone, or another OAP\]) in delaying time to treatment failure....
What is the current status of trial NCT02431702?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 337 participants. The study started on 2015-07-08. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT02431702?
The interventions under investigation include: Haloperidol (DRUG), Olanzapine (DRUG), Aripiprazole (DRUG), Perphenazine (DRUG), Oral Paliperidone ER (DRUG).
Who is sponsoring clinical trial NCT02431702?
This trial is sponsored by Janssen Scientific Affairs, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.